XXXX induces neuroprotection against experimental @entity64 in @entity35 by down-regulation of @entity6096 via activating @entity7131 .

@entity3958 @entity64 @entity2657 @entity2500 @entity7131 @entity51 @entity6096 @entity1188 @entity25695 @entity35 @entity3957
UNASSIGNED: @entity3957 ( @entity3958 ) is now known as an important neuromodulator in the central nervous system. The aim of the current study was to investigate whether exogenous @entity3958 gas can attenuate @entity2657 induced by experimental @entity64 and to clarify the potential mechanisms. @entity35 underwent 2-h @entity2500 ( @entity2500 ) and received 40ppm or 80ppm @entity3958 inhalation for 3h at the beginning of reperfusion. The effects of @entity3958 were investigated by evaluating neurological function, @entity1188 size, @entity2657 volume, and @entity6096 ( @entity6096 ) protein expression at 24h after reperfusion. Moreover, to explore the possible mechanisms for the neuroprotective effects of @entity3958 , @entity7131 ( @entity7131 ) activity was detected and a @entity7131 inhibitor, @entity25695 , was used via intracerebral ventricular injection. Our results showed that 40ppm or 80ppm @entity3958 inhalation significantly reduced @entity51 , @entity1188 size, and @entity2657 after @entity2500 . The expression of @entity6096 in the peri- @entity1188 area of brain was also inhibited after inhalation of @entity3958 . @entity7131 was activated by @entity3958 treatment and the @entity7131 inhibitor attenuated the neuroprotection of @entity3958 with an increased @entity6096 expression at the same time. In conclusion, @entity3958 inhalation attenuates @entity2657 , reduces @entity1188 volume, and improves neurologic function in a @entity35 experimental @entity64 model. The therapeutic benefits of @entity3958 inhalation are associated with down-regulation of @entity6096 expression via activating @entity7131 .
